Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
04/27/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)03/29/17
Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization03/21/17
Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event03/16/17
Investor Events More
There are currently no events scheduled.